FRCA Notes


Phenobarbital


  • A long-acting barbiturate
  • The phenyl side group on position R2 of its pyrimidine ring has anticonvulsant activities
  • It can be used to treat all types of epilepsy (except absence seizures) including status epilepticus
  • Of note, the anti-epileptic drugs phenytoin and primidone are metabolised to phenobarbital

  • Odourless, white, crystalline powder
  • Available for the oral route; onset in 30mins

Absorption

  • Oral bioavailability approximately 90%

Distribution

  • Volume of distribution of 0.7L/kg
  • 50% protein bound

Metabolism

  • 75% hepatic (CYP2C19)
  • 25% excreted unchanged in urine

Excretion

  • Clearance 11ml/kg/min
  • Half life 3-5hrs
  • Renal elimination is increased by alkalising urine as it is a weak acid

Respiratory

  • Respiratory depression

Cardiovascular

  • Cardiovascular depression

Neurological

  • Sedation
  • Impairment of cognition and motor skills
  • Hyperkinesia
  • Behavioural disturbance

Haematological

  • Megaloblastic anaemia

Other

  • Powerful enzyme inducer, interacting with warfarin, other anticonvulsants and the OCP
  • Hypersensitivity reactions
  • Osteomalacia